 | • レポートコード：GIR-2104Z00720 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、α1-アンチトリプシン欠乏症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。α1-アンチトリプシン欠乏症治療の種類別市場規模（増強療法、気管支拡張薬、コルチコステロイド、酸素療法）、用途別市場規模（病院、専門診療所、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・α1-アンチトリプシン欠乏症治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Baxter、AstraZeneca、Grifols、Teva Pharmaceutical Industries、Boehringer Ingelheim、Kamada Ltd、GlaxoSmithKline、CSL Behring、Takeda、LFB Biomedicaments、Abeona Therapeutics、Biogen、Applied Genetic Technologies、Baxalta、Arrowhead Research Corporation、ProBioGen、Chiesi Pharmaceuticals、Curaxys、ProMetic Life Sciences ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：増強療法、気管支拡張薬、コルチコステロイド、酸素療法 ・用途別分析2016年-2026年：病院、専門診療所、薬局 ・α1-アンチトリプシン欠乏症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・α1-アンチトリプシン欠乏症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・α1-アンチトリプシン欠乏症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・α1-アンチトリプシン欠乏症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・α1-アンチトリプシン欠乏症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Alpha 1 Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Alpha 1 Antitrypsin Deficiency Treatment size is estimated to be USD 1433 million in 2025 from USD 1184.2 million in 2019, with a change XX% between 2019 and 2020. The global Alpha 1 Antitrypsin Deficiency Treatment market size is expected to grow at a CAGR of 4.9% for the next five years.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Market segment by Application, can be divided into
Hospitals
Specialty Clinics
Pharmacies
Market segment by players, this report covers
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment
1.2 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Type
1.2.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2020
1.2.3 Augmentation Therapy
1.2.4 Bronchodilators
1.2.5 Corticosteroids
1.2.6 Oxygen Therapy
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market by Application
1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Forecast
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast by Region
1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region, (2016-2021)
1.5.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
1.6.2 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
1.6.3 Alpha 1 Antitrypsin Deficiency Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Baxter
2.2.1 Baxter Details
2.2.2 Baxter Major Business
2.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.2.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Baxter Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Grifols
2.4.1 Grifols Details
2.4.2 Grifols Major Business
2.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.4.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Grifols Recent Developments and Future Plans
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.6.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Kamada Ltd
2.7.1 Kamada Ltd Details
2.7.2 Kamada Ltd Major Business
2.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.7.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Kamada Ltd Recent Developments and Future Plans
2.8 GlaxoSmithKline
2.8.1 GlaxoSmithKline Details
2.8.2 GlaxoSmithKline Major Business
2.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.8.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 GlaxoSmithKline Recent Developments and Future Plans
2.9 CSL Behring
2.9.1 CSL Behring Details
2.9.2 CSL Behring Major Business
2.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 CSL Behring Recent Developments and Future Plans
2.10 Takeda
2.10.1 Takeda Details
2.10.2 Takeda Major Business
2.10.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.10.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Takeda Recent Developments and Future Plans
2.11 LFB Biomedicaments
2.11.1 LFB Biomedicaments Details
2.11.2 LFB Biomedicaments Major Business
2.11.3 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.11.4 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 LFB Biomedicaments Recent Developments and Future Plans
2.12 Abeona Therapeutics
2.12.1 Abeona Therapeutics Details
2.12.2 Abeona Therapeutics Major Business
2.12.3 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.12.4 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Abeona Therapeutics Recent Developments and Future Plans
2.13 Biogen
2.13.1 Biogen Details
2.13.2 Biogen Major Business
2.13.3 Biogen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.13.4 Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Biogen Recent Developments and Future Plans
2.14 Applied Genetic Technologies
2.14.1 Applied Genetic Technologies Details
2.14.2 Applied Genetic Technologies Major Business
2.14.3 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.14.4 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Applied Genetic Technologies Recent Developments and Future Plans
2.15 Baxalta
2.15.1 Baxalta Details
2.15.2 Baxalta Major Business
2.15.3 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.15.4 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Baxalta Recent Developments and Future Plans
2.16 Arrowhead Research Corporation
2.16.1 Arrowhead Research Corporation Details
2.16.2 Arrowhead Research Corporation Major Business
2.16.3 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.16.4 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Arrowhead Research Corporation Recent Developments and Future Plans
2.17 ProBioGen
2.17.1 ProBioGen Details
2.17.2 ProBioGen Major Business
2.17.3 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.17.4 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 ProBioGen Recent Developments and Future Plans
2.18 Chiesi Pharmaceuticals
2.18.1 Chiesi Pharmaceuticals Details
2.18.2 Chiesi Pharmaceuticals Major Business
2.18.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.18.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Chiesi Pharmaceuticals Recent Developments and Future Plans
2.19 Curaxys
2.19.1 Curaxys Details
2.19.2 Curaxys Major Business
2.19.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.19.4 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Curaxys Recent Developments and Future Plans
2.20 ProMetic Life Sciences
2.20.1 ProMetic Life Sciences Details
2.20.2 ProMetic Life Sciences Major Business
2.20.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.20.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 ProMetic Life Sciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.2.2 Top 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2016-2021)
5.2 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
6.3.2 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
7.3.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.3 France Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2016-2026)
8.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.5 India Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
9.2 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
9.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
9.3.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 9. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Baxter Corporate Information, Head Office, and Major Competitors
Table 11. Baxter Major Business
Table 12. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 13. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 17. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Grifols Corporate Information, Head Office, and Major Competitors
Table 19. Grifols Major Business
Table 20. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 21. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Industries Major Business
Table 24. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 25. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim Major Business
Table 28. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 29. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Kamada Ltd Corporate Information, Head Office, and Major Competitors
Table 31. Kamada Ltd Major Business
Table 32. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 33. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 35. GlaxoSmithKline Major Business
Table 36. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 37. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 39. CSL Behring Major Business
Table 40. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 41. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Takeda Corporate Information, Head Office, and Major Competitors
Table 43. Takeda Major Business
Table 44. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 45. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. LFB Biomedicaments Corporate Information, Head Office, and Major Competitors
Table 47. LFB Biomedicaments Major Business
Table 48. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 49. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Abeona Therapeutics Corporate Information, Head Office, and Major Competitors
Table 51. Abeona Therapeutics Major Business
Table 52. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 53. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Biogen Corporate Information, Head Office, and Major Competitors
Table 55. Biogen Major Business
Table 56. Biogen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 57. Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Applied Genetic Technologies Corporate Information, Head Office, and Major Competitors
Table 59. Applied Genetic Technologies Major Business
Table 60. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 61. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Baxalta Corporate Information, Head Office, and Major Competitors
Table 63. Baxalta Major Business
Table 64. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 65. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Arrowhead Research Corporation Corporate Information, Head Office, and Major Competitors
Table 67. Arrowhead Research Corporation Major Business
Table 68. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 69. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. ProBioGen Corporate Information, Head Office, and Major Competitors
Table 71. ProBioGen Major Business
Table 72. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 73. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Chiesi Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 75. Chiesi Pharmaceuticals Major Business
Table 76. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 77. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Curaxys Corporate Information, Head Office, and Major Competitors
Table 79. Curaxys Major Business
Table 80. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 81. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. ProMetic Life Sciences Corporate Information, Head Office, and Major Competitors
Table 83. ProMetic Life Sciences Major Business
Table 84. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 85. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Players (2019-2021)
Table 87. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2019-2021)
Table 88. Breakdown of Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 89. Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
Table 90. Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions in the Past Five Years
Table 91. Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
Table 92. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Type (2016-2021)
Table 93. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2016-2021)
Table 94. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Type (2021-2026)
Table 95. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021)
Table 96. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Application (2021-2026)
Table 97. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 98. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 99. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 100. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 101. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 102. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 103. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 104. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 105. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 106. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 107. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 108. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 109. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 110. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 111. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 112. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 113. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2016-2021) & (USD Million)
Table 114. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2021-2026) & (USD Million)
Table 115. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 116. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 117. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 118. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 119. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 120. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
Table 121. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2016-2021) & (USD Million)
Table 122. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2026) & (USD Million)
Table 123. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2016-2021) & (USD Million)
Table 124. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2026) & (USD Million)
Table 125. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2016-2021) & (USD Million)
Table 126. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2020
Figure 3. Augmentation Therapy
Figure 4. Bronchodilators
Figure 5. Corticosteroids
Figure 6. Oxygen Therapy
Figure 7. Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application in 2020
Figure 8. Hospitals Picture
Figure 9. Specialty Clinics Picture
Figure 10. Pharmacies Picture
Figure 11. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2016-2026)
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region in 2020
Figure 15. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Figure 20. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Figure 21. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Figure 22. Pfizer Recent Developments and Future Plans
Figure 23. Baxter Recent Developments and Future Plans
Figure 24. AstraZeneca Recent Developments and Future Plans
Figure 25. Grifols Recent Developments and Future Plans
Figure 26. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 27. Boehringer Ingelheim Recent Developments and Future Plans
Figure 28. Kamada Ltd Recent Developments and Future Plans
Figure 29. GlaxoSmithKline Recent Developments and Future Plans
Figure 30. CSL Behring Recent Developments and Future Plans
Figure 31. Takeda Recent Developments and Future Plans
Figure 32. LFB Biomedicaments Recent Developments and Future Plans
Figure 33. Abeona Therapeutics Recent Developments and Future Plans
Figure 34. Biogen Recent Developments and Future Plans
Figure 35. Applied Genetic Technologies Recent Developments and Future Plans
Figure 36. Baxalta Recent Developments and Future Plans
Figure 37. Arrowhead Research Corporation Recent Developments and Future Plans
Figure 38. ProBioGen Recent Developments and Future Plans
Figure 39. Chiesi Pharmaceuticals Recent Developments and Future Plans
Figure 40. Curaxys Recent Developments and Future Plans
Figure 41. ProMetic Life Sciences Recent Developments and Future Plans
Figure 43. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players in 2020
Figure 44. Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 45. Global Top 3 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2020
Figure 46. Global Top 10 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2020
Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 48. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type in 2020
Figure 49. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Type (2021-2026)
Figure 50. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application in 2020
Figure 51. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Application (2021-2026)
Figure 52. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 53. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 54. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 55. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 59. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 60. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 61. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 67. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 68. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2016-2026)
Figure 69. China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 76. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 77. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 78. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Type (2016-2026)
Figure 81. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Application (2016-2026)
Figure 82. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2016-2026)
Figure 83. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Methodology
Figure 87. Research Process and Data Source
世界のアルファ-アンチトリプシン欠乏症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Alpha- Antitrypsin Deficiency Treatment Market The global Alpha- Antitrypsin Deficiency Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…- 世界のアデノシンデアミナーゼ欠損症（ADA）治療市場規模・現状・予測（2021年-2027年） Adenosine deaminase deficiency is an autosomal recessive metabolic disorder that causes immunodeficiency. It occurs in fewer than one in 100,000 live births worldwide. Market Analysis and Insights: Global Adenosine Deaminase Deficiency Treatment Market The global Adenosine Deaminase Deficiency Treat…
- 世界の第IX因子欠乏症治療市場規模・現状・予測（2021年-2027年） Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B. In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market dur…
- 世界の第IX因子欠乏症治療市場 2021：企業別、地域別、種類・用途別 The Factor IX Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …
- 世界のビタミンD欠乏症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Vitamin D Deficiency Treatment Market The global Vitamin D Deficiency Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data int…